Brief: Aurinia's Long Term Phase 3 Data Shows Lupkynis Preserved Kidney Function Up To Three Years
19/07/2023 17:06
July 19 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O :
* LONG TERM PHASE 3 DATA PUBLISHED IN ARTHRITIS & RHEUMATOLOGY SHOWS
LUPKYNIS®
(VOCLOSPORIN) PRESERVED KIDNEY FUNCTION UP TO THREE YEARS IN LUPUS NEPHRITIS
PATIENTS WITH NO NEW OR UNEXPECTED ADVERSE EVENTS
Source text for Eikon: ID:nBw2jdHZda
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death